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Background: A report of the chloroquine and amodiaquine resistance pfcrt-SVMNT haplotype in Tanzania raises
concern about high-level resistance to the artesunate-amodiaquine combination treatment widely employed in
Africa. Mutations in the pfmdr1 multi-drug resistance gene may also be associated with resistance, and a highly
polymorphic microsatellite (ms-4760) of the pfnhe1 gene involved in quinine susceptibility has not been surveyed
in Tanzania.
Methods: A total of 234 samples collected between 2003 – 2006 from an observational birth cohort of young
children in Muheza, Tanzania were analysed. In these children, 141 cases of P. falciparum infections were treated
with AQ and 93 episodes were treated with QN. Haplotypes of pfcrt and pfmdr1 were determined by a Taqman
assay, and ms-4760 repeats in pfnhe1 were assessed by nested PCR amplification and direct sequencing. Parasite
population diversity was evaluated using microsatellite markers on five different chromosomes.
Results: The pfcrt-CVIET haplotype was present alone in 93.6% (219/234) of the samples over the study period; the
wild-type chloroquine- and amodiaquine-sensitive haplotype pfcrt-CVMNK was present in 4.3% (10/234) of the
samples; and both haplotypes were present in 2.1% (5/234) of the samples. No significant change in wild-type
pfcrt-CVMNK prevalence was evident over the 4-year period of the study. The pfcrt-SVMNT haplotype associated
with high-level amodiaquine resistance was not detected in this study. The pfmdr1 locus was genotyped in 178 of
these samples. The pfmdr1-YYNY haplotype predominated in 67.4% (120/178) of infections and was significantly
associated with the pfcrt-CVIET haplotype. All samples carried the wild-type pfmdr1-N1042 codon. The ms-4760
repeat on pfnhe1 locus displayed 12 distinct haplotypes with ms-4760-1 predominating in the population. Analysis
of these haplotypes showed no association of a particular haplotype with quinine treatment outcome.
Conclusion: The pfcrt-CVIET chloroquine resistance haplotype dominated in the collection of P. falciparum samples
from Muheza. The pfcrt-SVMNT haplotype, which threatens the efficacy of amodiaquine and was reported in the
same time period from Korogwe, Tanzania, 40 Km from Muheza, was not detected. Relative low prevalence of
pfcrt-SVMNT in Africa may result from genetic or other factors rendering P. falciparum less supportive of this
haplotype than in South America or other regions.
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Parasite resistance to anti-malarials including artemisinins
[1,2] poses a great challenge to Plasmodium falciparum
malaria control efforts. Monitoring parasite haplotypes
that predict susceptibility to major anti-malarials can
guide treatment policies. Chloroquine (CQ) and amodia-
quine (AQ) resistance are linked to mutations in the P.
falciparum CQ resistance transporter gene pfcrt [3-5].
Two major haplotypes associated with these forms of drug
resistance are pfcrt-CVIET in Africa and regions of Asia,
and pfcrt-SVMNT in regions of South America, Asia and
The Pacific. The pfcrt-CVIET haplotype swept the African
continent in the wake of widespread CQ use [6].
Evidence suggests that the prevalence of the pfcrt-
CVIET haplotype has subsided with repopulation of CQ-
sensitive pfcrt-CVMNK parasites in several regions where
sulphadoxine-pyrimethamine (SP) or artemisinin-based
combination therapy (ACT) replaced CQ as drugs recom-
mended for the treatment of P. falciparum malaria [7-20].
This phenomenon has not been observed in South America
where, despite removal of CQ and AQ, mutant pfcrt-
SVMNT parasites remain highly prevalent [21]. A possible
explanation for the faster declines of pfcrt-CVIET preva-
lence in Africa and Southeast Asia is that pfcrt-CVIET is
less fit than pfcrt-SVMNT relative to wild-type pfcrt-
CVMNK in the absence of drug pressure [22]. However,
much remains to be understood about parasite fitness and
drug resistance [23].
Polymorphisms in another transporter gene (pfmdr1)
encoding P-glycoprotein homologue 1 (PfPgH-1, also
known as PfMDR1) have also been associated with P.
falciparum responses to AQ and its major metabolite,
monodesethylamodiaquine (MDAQ), as well as to other
drugs including artemisinin derivatives [24-26]. In vitro
drug responses from Nigerian isolates suggest that the
pfmdr1-86Y codon polymorphism may be associated with
decreased susceptibility to AQ [27]. This same poly-
morphism together with pfmdr1-1246Y has been associ-
ated with AQ treatment failures [28-30]. Other studies
found an increased frequency of the pfmdr1-YYY triplet
(codon positions 86, 184, 1246) in recrudescent and
recurrent infections after treatment with AQ [30-33] or
artesunate-amodiaquine (AS/AQ) [34].
Quinine (QN) remains an efficacious alternative treat-
ment for malaria, including severe malaria and malaria
in pregnancy. QN resistance is not widespread in malaria
endemic areas possibly due to the multigenic nature of
its resistance mechanism. Polymorphisms in both pfcrt
[4,35] and pfmdr1 [25,36] have been associated with QN
susceptibility in vitro. The P. falciparum homologue
sodium-hydrogen ion exchanger gene (pfnhe1) located
in chromosome 13 has been linked to moderate QN re-
sistance: polymorphisms in one of three microsatellite re-
gions of pfnhe1, namely two or more repeats of DNNNDin ms-4760, were associated with a higher QN IC50 in the
progeny of a genetic cross (HB3 ×Dd2), in culture-
adapted clinical isolates and in laboratory lines [37]. Data
from patient isolates tested in vitro for their QN response
showed an association of two or more DNNND of the
pfnhe1-ms-4760 with higher IC50 values in some [38-41]
but not all studies [42-44]. In a review of the genetic
markers of QN resistance, Okombo and colleagues have
grouped the ms-4760 into blocks of particular repeats
(block I to VI) [45]. A recent worldwide analysis of ms-
4760 sequences identified a high diversity of haplotypes as
well as an apparent absence of some of these haplotypes
from endemic regions of Africa [46].
Reports of the pfcrt-SagtVMNT (AGT codon for serine)
haplotype in Tanzania [47] and Cameroon [48], in addition
to the pfcrt-StctVMNT (TCT codon for serine) haplotype
in Angola [49], raise concern whether AQ treatment fail-
ures may increase, particularly if the P. falciparum para-
sites also carry pfmdr1 N86 and 1042D codons that,
together with pfcrt-SVMNT, are associated with the high
levels of AQ resistance found in South America [5]. Spread
of the pfcrt-SVMNT and pfmdr1 N86/1042D combination
would pose a major threat to AS/AQ combination cur-
rently used in 25 African countries for uncomplicated
malaria [50]. In light of these reports, a survey for the
presence of pfcrt-SVMNT and/or pfmdr1 N86/1042D
in samples collected from children treated for malaria
in Muheza, located approximately 40 kilometres west
of Korogwe District where the observation of pfcrt-
SVMNT was reported [47], was undertaken in this study.
In addition, the diversity of pfnhe1 ms-4760 in children




Samples analysed in this study had been collected from
children aged 3 – 33 months as part of the Mother-
Offspring Malaria Study performed in Muheza, north-
eastern Tanzania, between 2003 and 2006 (Figure 1).
The details of this observational birth cohort study were
approved by Tanzanian and US ethical review boards,
and signed informed consent was obtained from all
mothers for children to participate in the study, as previ-
ously reported [51,52]. Confirmation of infection with P.
falciparum was performed by microscopic examination
of blood smears. Blood samples from children who pre-
sented with symptoms consistent with clinical malaria
(headache, nausea, vomiting, temperature ≥ 37.5°C) were
stored on filter paper (FP). Parasite levels in the blood
were reported as the number of parasites (pa) per 200
white blood cells (pa/200 WBC), and parasitaemia (pa/μl)
estimates were calculated by assuming an average of 8000
WBCs/μl. Standard treatment for children with less than
Figure 1 Geographic locations of Muheza and Korogwe. Map of Tanzania showing Tanga Region. Inset; the locations of Muheza District
(present report) and Korogwe District where the presence of pfcrt-SVMNT was previously reported [47].
Gadalla et al. Malaria Journal  (2015) 14:129 Page 3 of 102,500 pa/200 WBC was a 3-day 25-mg/kg AQ regimen
(10, 10, 5 mg/kg/day). Children who failed AQ treatment
or whose parasitaemia was above 2,500 pa/200 WBC were
treated with QN at 10 mg/kg every 8 hours for 7 days [51].
Children unable to take the drugs orally were treated with
intravenous QN twice daily until the child was able to take
QN orally and complete the 7-day regimen.
DNA extraction and genotyping
An area of approximately 7 mm2 from FP containing dry
blood was cut with a pair of scissors that were deconta-
minated with 70% ethanol between samples. The FP was
soaked overnight in 20% Chelex®. The supernatant was
removed to a clean tube and the FP was washed twice in
1 ml 1X PBS. DNA was extracted using the QIAamp
DNA mini kit (Qiagen Inc., USA) per the manufacturer’s
recommendations and eluted in 50 μl of AE elution buffer.
Samples from a non-template control (NTC) obtained by
spotting parasite negative AB+ human blood on FP and
from a piece of FP not containing any blood were included
in each extraction batch (30 samples) to assure absence of
contamination.
To assess the pfcrt haplotypes (CVMNK, CVIET, or
SagtVMNT codons at positions 72–76), a Taqman assay
was performed in a 25 μl volume containing 12.5 μl ofRotor-Gene Probe PCR Kit (Qiagen Inc., USA), 0.3 μM of
each primer (PfCRT-D1 and PfCRTD2), 0.1 μM of each
probe (crt76-CVMNK, crt76-CVIET, crt76-SagtVMNT)
and 5 μl of sample DNA as previously described [53]. In
addition, a probe that detects the StctVMNT haplotype
(crt76-StctVMNT 5′- TCT GTA ATG AAT ACA ATT
TTT GCTAA-3′) was designed for this study.
Pfmdr1 haplotypes (codons 86, 184, 1042, and 1246)
were determined by a Taqman assay employing the
primers and probes listed in Table 1. Multiplexed reac-
tions were run for each pair of codons in a single tube
in a Rotor Gene 3000 (Qiagen Inc., USA) with four de-
tection channels. The first tube contained primers and
probes specific for codons 86 and 1246 and the second
tube contained primers and probes specific for codons
184 and 1042. The 25 μl reaction contained 12.5 μl of
Rotor-Gene Multiplex PCR Kit mixture (Qiagen Inc.,
USA), final concentrations of 0.3 μM of each primer, 0.1
μM of each probe and 5 μl of DNA. For detection of co-
dons 86 and 1246, samples were subjected to an initial
heating step of 95°C for 5 min followed by 40 cycles of
95°C for 15 s and 52°C for 30 s. For detection of codons
184 and 1042, reactions were subjected to an initial heat-
ing step of 95°C for 5 min followed by 40 cycles of 95°C
15 s and 50°C for 30 s. At least two DNA positive
Table 1 Primers and probes sequences used to amplify and detect SNPs in pfmdr1
Position Primer/Probe Sequence 5′→ 3′
86
Pfmdr1-86F CCT TTT TTT ATA TCT GTG TTT GGT G
Pfmdr1-86R TTA TTA TCA TGA AAT TGT CCA TCT TG
Pfmdr1-86N ROX-AAA GAA CAT GAA TTT AGG TGA TGA-BHQ-2a
Pfmdr1-86Y Cy5- AAA GAA CAT GTA TTT AGG TGA TGA-BHQ-2a
184
Pfmdr1-184F TTA TAA CAA TTT TTA CAT ATG CCA GTT CC
Pfmdr1-184R TCT TAT TAC ATA TGA CAC CAC AAA C
Pfmdr1-184Y JOE-TTA GGT TTA TAT ATT TGG TCA TTAAT-BHQ-1a
Pfmdr1-184F FAM -TTA GGT TTA TTT ATT TGG TCA TTAAT-BHQ-1a
1042
Pfmdr1-1042F GAA GAA TTA TTG TAA ATG CAG C
Pfmdr1-1042R CCT TTT AAG GAC ATT AAT TTT C
Pfmdr1-1042N ROX-ATT ATT TAT TAA TAG TTT TGC-BHQ2a
Pfmdr1-1042D Cy5-ATT ATT TAT TGA TAG TTT TGC-BHQ2a
1246
Pfmdr1-1246F TGC AGA AGA TTAT ACT GTA TTT AAT A
Pfmdr1-1246R GCA AAC TTA CTA ACA CGT TTA ACA
Pfmdr1-1246D JOE- TAT AAC TTA AGA GAT CTT AGA AAC-BHQ-1a
Pfmdr1-1246Y FAM-TAT AAC TTA AGA TAT CTT AGA AAC- BHQ-1a
Mutant bases of the Pfmdr1-86Y, Pfmdr1-184F, Pfmdr1-1042D and Pfmdr1-1246Y primers are shown in bold font. ROX, Cy5, JOE, FAM indicate fluorescent reporter
dyes; BHQ-1a and BHQ-2a denote Black Hole Quencher Dyes 1a and 2a, respectively.
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phisms of P. falciparum clones 3D7, Dd2, HB3 and 7G8
were included in each experiment. Reactions with NTC
and FP extractions (described above) and with deionized
water substituted for template DNA were employed as
negative controls in each experiment. Direct sequencing
of the Taqman assay products from 45 samples was also
performed to verify the polymorphisms in pfmdr1.
A 350 bp region of the pfnhe1 gene was amplified in 94 of
the 99 QN treated samples using nested PCR, as previously
described [41]. PCR products were purified by EXOSAP-it
(USB, Ohio, USA) and bidirectionally sequenced.
Diversity assessment of 100 randomly selected samples
was performed with six polymorphic microsatellite markers
present in distinct chromosomes; polyα, TA81, TA1, TA60
and TAA87 [54,55], and 299812 [56]. The reverse primer
for each marker was fluorescently labeled and PCR prod-
ucts were analysed in an ABI 3730XL Genetic Analyzer
(Life Technologies, Carlsbad, CA, USA). Microsatellite data
were analysed with Gene Mapper software (v3.2). A mixed
microsatellite haplotype was assigned when the minor sig-
nal was at least 33.3% of the major signal [57]. Polyclonal-
ity was scored if mixed signals were observed from at least
two microsatellites.
Results
Parasitaemia and treatment outcomes of children
receiving AQ or QN
Samples available from the Muheza Mother-Offspring
Malaria Study included filter paper blood spots from 141children who presented to the clinic with a new episode
of P. falciparum parasitaemia, had no history of anti-
malarial treatment within the preceding 4 weeks, and
were prescribed 3 doses of AQ (Figure 2, see Additional
file 1). Of these 141 cases that were treated with AQ, 69
developed microscopic parasitaemia again within four
weeks, requiring additional clinical care, while no recur-
rent parasitaemia was observed in 72 cases. Ninety-three
samples were available from cases treated with QN. These
samples were from seven cases requiring QN within four
weeks of AQ treatment and an additional 86 cases of chil-
dren presenting with parasite densities ≥ 2,500 pa/200
WBC (est. 100,000 pa/μl; 70 cases) or who were unable to
take oral AQ therapy (16 cases; Figure 2).
Presenting parasite densities in the samples from all
141 + 93 = 234 AQ- or QN-treated cases ranged from 40
to 1,119,280 pa/μl with a geometric mean of 30,107 pa/μl
(average LN (pa/μl) = 10.313). Geometric means of pre-
senting parasite densities were 11,196 pa/μl (average LN
(pa/μl) = 9.323) in the cases treated with AQ and were
134,903 (average LN (pa/μl) = 11.812) in the cases treated
with QN (Table 2). Presenting parasite densities ranged
from 40 – 96,800 pa/μl in cases that showed no recur-
rence after AQ treatment and from 4,480 – 1,119,280
pa/μl in cases with no recurrence after QN treatment,
while parasite densities in cases of recurrent parasitaemia
were 120–204,480 pa/μl after AQ treatment and 1,680 –
744,800 pa/μl after QN treatment. By two-tailed t-tests
of LN (pa/μl) average and standard deviation values, there
were no significant differences in the geometric mean
Figure 2 Flowchart of malaria cases, treatments and outcomes in the Muheza Mother-Offspring Malaria Study.
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develop recurrent parasitaemia after treatment with AQ
(p = 0.78) or QN (p = 0.37).
pfcrt haplotypes and treatment outcomes in the Muheza
cases
Haplotypes of pfcrt were determined for all 234 cases:
219/234 (93.6%) of the samples carried pfcrt-CVIET
alone, 10/234 (4.3%) carried pfcrt-CVMNK alone, and 5/
234 (2.1%) carried both of these haplotypes (Table 3).
The South American pfcrt-SVMNT haplotype was not
detected by the Taqman assay or sequencing in any of
the samples in this study. By year of collection, the oc-
currence of pfcrt-CVMNK or mixed pfcrt-CVMNK/
pfcrt-CVIET in the samples was 1/32 in 2003 (3.1%), 6/
117 in 2004 (5.1%), 8/76 in 2005 (10.5%) and 0/9 in
2006 (0.0%). The different percentages of pfcrt-CVMNKTable 2 Clinical data of the AQ-treated and QN-treated
groups
AQ-treated group QN-treated group
Number of episodes 141 93
Mean Hb (g/dl) 10.5 10.6
(range) (3.0 – 18.8) (4.5 – 18.3)
Mean Temperature °C 37.6 38.0




(range) (40 – 204,480) (1,680 - 1,119,280)
Hb S AA 132 86
Hb S AS 7 6
Hb type not determined 2 1haplotypes in these samples were not statistically signifi-
cant for a trend between 2003 and 2006 (chi-square test
for trend p = 0.27).
Among the cases prescribed AQ and carrying the pfcrt-
CVIET or mixed pfcrt-CVMNK/pfcrt-CVIET haplotype,
only 70/137 (51.1%) remained clear of recurrent parasit-
aemia for more than four weeks. Similarly, only 2/4 (50%)
of cases receiving AQ and carrying pfcrt-CVMNK alone
remained clear of recurrent parasitaemia for more than
four weeks. QN treatment of infections carrying the pfcrt-
CVIET or mixed pfcrt-CVMNK/pfcrt-CVIET haplotype
cleared 57/87 (65.5%) of the parasitaemia for more than
four weeks. Similarly, 4/6 (66.7%) of infections receiving
QN and carrying the pfcrt-CVMNK haplotype alone
remained clear of recurrent parasitaemia for more than
four weeks.
Distribution of pfmdr1 haplotypes
From the 234 samples described above, 178 samples were
successfully assessed for four pfmdr1 codon polymor-
phisms: N86 or 86Y; Y184 or 184F; N1042 or 1042D;
D1246 or 1246Y (Table 3, Additional file 1). Codons of
the pfmdr1-YYNY haplotype either alone or mixed with
polymorphisms of other pfmdr1 alleles occurred in 137/
178 (77.0%) of the samples. Further analysis showed that
the codons of pfmdr1-YYNY were present in 135/169
(79.9%) of the pfcrt-CVIET-containing samples but in only
2/9 (22.2%) of samples containing pfcrt-CVMNK alone:
this difference was found to be statistically significant
(Fishers’ exact p < 0.001). In contrast, there was no evident
association between pfmdr1-YYND and pfcrt-CVIET
(Fisher’s Exact p = 0.63). The pfmdr1-86Y polymorphism
occurred either alone or mixed with pfmdr1-N86 in 163/
178 (91.6%) samples, while pfmdr1-1246Y occurred either
alone or mixed with pfmdr1-D1246 in 146/178 (82.0%)
Table 3 Distribution of PfCRT and PfMDR1 haplotypes in the study population 2003 – 2006
Year
2003 2004 2005 2006 TOTAL
PfCRT amino acid positions 72–76
CVMNK only 0.0% (0) 3.4% (4) 7.9% (6) 0% (0) 4.3% (10)
CVIET only 96.9% (31) 94.9% (111) 89.5% (68) 100% (9) 93.6% (219)
CVMNK & CVIET mixed 3.1% (1) 1.7% (2) 2.6% (2) 0% (0) 2.1% (5)
Number of samples 32 117 76 9 234
PfMDR1 amino acid positions 86, 184, 1042, 1246
YYNY only 67.7% (12) 67.8% (59) 66.2% (43) 75% (6) 67.4% (120)
YYNY mixed* 5.6% (1) 11.5% (10) 9.2% (6) 0.0% (0) 9.6% (17)
YYND only 16.7% (3) 10.3% (9) 13.8% (9) 12.5% (1) 12.4% (22)
YYND mixed** 0.0% (0) 10.3% (9) 7.7% (5) 0.0% (0) 7.9% (14)
Other haplotypes 11.1% (2) 6.9% (6) 9.2% (6) 12.5% (1) 8.4% (15)
Number of samples 18 87*** 65*** 8 178***
*Mixed with codons of other haplotypes, including 10 YYND (6 in 2004; 4 in 2005).
**Mixed with codons of other haplotypes, including 10 YYNY (6 in 2004; 4 in 2005).
***Total is corrected for the YYNY + YYND mixed samples that are entered twice, as both YYNY mixed and as YYND mixed samples.
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in 174/178 (97.8%) samples. All 178 isolates carried the
wild-type pfmdr1-N1042 polymorphism.
Of the 178 samples typed for pfmdr1 polymorphisms,
95 were from children who received AQ treatment. AQ
cleared 47/95 (49.5%) of these infections with no recur-
rence of parasitaemia for more than four weeks. The
pfmdr1-86Y polymorphism was detected in 45/47 (95.7%)
of children who remained clear of parasitaemia and in
45/48 (93.8%) of the children who developed recurrent
parasitaemia within four weeks (Fishers’ exact p = 1.00).
The pfmdr1-1246Y polymorphism was detected in 38/47
(78.7%) of children who remained clear of parasitaemia
and in 40/48 (83.3%) of the children who developed recur-
rent parasitaemia within four weeks; this difference was
also not significant (Fishers’ exact p = 0.79).
Eighty-three of the 178 samples typed for pfmdr1 poly-
morphisms were from children who received QN treat-
ment. QN cleared 56/83 (67.5%) of these infections with
no recurrence of parasitaemia for more than four weeks.
The pfmdr1-86Y polymorphism was present in 49/56
(87.5%) of children who remained clear of parasitaemia
and in 24/27 (88.9%) of the children who developed recur-
rent parasitaemia within four weeks (Fishers’ exact p =
1.00). The pfmdr1-1246Y polymorphism was present in
46/56 (82.1%) infections of children who remained clear
of parasitaemia and in 22/27 (81.5%) of the children who
developed recurrent parasitaemia within four weeks; this
difference was not significant (Fishers’ exact p = 1.00).
pfnhe1 ms-4760 repeat haplotypes in cases treated with QN
Of the 93 cases treated with QN, a 350 bp region of the
pfnhe1 gene containing the ms-4760 repeat region wassuccessfully amplified and sequenced from 79/93 (85%)
sample preparations. Twelve different haplotypes of ms-
4760 were observed, including two previously unreported
haplotypes (ms-4760-102 and ms-4760-103; Figure 3).
The most prevalent haplotype was ms-4760-1 (two
DNNND repeats in block II), observed in 40/79 (50.6%)
of the samples; the second most frequent haplotype, ms-
4760-3 (one DNNND repeat in block II) occurred in
17.7% (14/79) of samples. Sequences of the observed hap-
lotypes and the number of samples in which each was de-
tected are presented in Figure 3.
Of the 79 QN-treated cases typed for ms-4760, 30.4%
(24/79) had returned with parasitaemia within four weeks
of treatment, while 69.6% (55/79) remained clear of para-
sitaemia. The presence of two or more repeats of DNNND
in ms-4670 was not a predictive factor for the return of
parasitaemia within 28 days (Fishers’ exact p = 0.77). Like-
wise, there was no association of two or more vs only one
DDNHNDNHNND repeat with return of parasitaemia
after the QN treatment (Fishers’ exact p = 1.0).
Population diversity
Four polymorphic microsatellites that reside near anti-
malarial drug resistance loci (MS-Polyα, chromosome 4;
MS-TAA81, chromosome 5; MS-299812, chromosome
8; MS-TA60, chromosome 13), and 2 microsatellites of
chromosome 6 (MS-TA1 and MS-TAA87) were typed in
100 randomly selected samples. For a given microsatel-
lite, a mixed haplotype was assigned if the fluorescence
peak from the minor band was at least 33% of the signal
from the major band.
PCR assays of the Polyα, MS-TAA81, MS-299812 and
MS-TA60 microsatellites detected 28, 19, 19 and 13 size
Figure 3 Predicted amino acid sequences from different pfnhe1 ms-4760 haplotypes in Muheza. The alignment includes repeats of the
pfnhe1 ms-4760 microsatellite in 79 samples. Left column: ms-4760 designation; center column: translated sequences from pfnhe1 microsatellite
repeat region including blocks I–VI [45]; right column: number of samples in which each haplotype was observed.
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some 13, a 70 bp band was obtained from 41.6% of
infections in either a single or mixed haplotype. On
chromosome 6, assays of MS-TAA87 detected 38 major
and 23 minor size polymorphisms, whereas assays of
MS-TA1 detected 23 major and 13 minor polymorphisms.
Most infections in the population differed from each other
at two or more microsatellites, consistent with a high level
of polyclonality and high transmission rates in this area
of Tanzania.
Discussion
Related mechanisms of drug action and resistance are
reflected in the structural similarities of CQ and AQ as
well as the evidence that pfcrt polymorphisms associated
with CQ resistance affect AQ efficacy. In a study of pfcrt
haplotypes and MDAQ responses in vitro, Warhurst et al.
[58] proposed that AQ resistance is associated with the
hydrophobicity of pfcrt-SVMNT polymorphisms. Amino
acid changes encoded by pfmdr1 that modulate responses
of CQ-resistant parasites have also been shown to affect
responses to AQ and MDAQ [24]. In the analysis of pfcrt
and pfmdr1 of two P. falciparum crosses, Sa et al. [5]
found that the highest in vitro IC50 levels for MDAQ oc-
curred in pfcrt-CVIET or pfcrt-SVMNT progeny carrying
either pfmdr1-NFCDY or pfmdr1-NFSDD (codon posi-
tions 86, 184, 1034, 1042, 1246), consistent with the asso-
ciation of the pfcrt-SVMNT/pfmdr1-NFCDY combination
with AQ failure in South America. These findings together
with reports of the pfcrt-SVMNT haplotype in Tanzania,
Angola, and Cameroon, raise the concern that if pfmdr1
with the 1042D change spread into Africa it could pro-
mote high-level AQ resistance where this drug is widely
deployed as a partner drug in ACT combinations [50].
In the present study, 234 samples collected over a four-
year period from Muheza, Tanzania were analysed for the
presence of pfcrt polymorphisms. The mutant pfcrt-CVIET
(Southeast Asian CQ-resistant form) predominated in theparasite population while the wild type (CQ-sensitive)
pfcrt-CVMNK form was present in 1/32 (3.1%) of samples
in 2003, 6/117 (5.1%) in 2004, 8/76 (10.5%) in 2005 and
0/9 (0%) in 2006; there was no statistically significant
trend for pfcrt-CVMNK prevalence among these samples
over the years. The pfcrt-SVMNT haplotype was not de-
tected in any of the samples analysed in this study. A high
level of genetic diversity among all samples was confirmed
by six highly polymorphic microsatellites of chromo-
somes 4, 5, 6 (two markers), 8 and 13. This diversity is an
expected outcome in high transmission areas such as
Muheza where the entomological inoculation rate has
been reported to be 405 infectious bites per year [59].
The pfmdr1-1042D polymorphism that is able to greatly
affect MDAQ susceptibility has not been reported in
Africa so far; however, three studies on the occurrence of
pfcrt-SVMNT in Africa did not provide data for pfmdr1
haplotypes [47-49]. The present study included assess-
ments of 178 Muheza samples for pfmdr1 polymorphisms
at codon positions 86, 184, 1042 and 1246. All 178 sam-
ples were found to encode only pfmdr1-N1042 with no
evidence for the presence of pfmdr1-1042D. Consistent
with previous suggestions that pfcrt and pfmdr1 polymor-
phisms in Asia and Africa may be maintained by substan-
tially different mechanisms than in South America [60],
the pfmdr1-1042D amino acid change may be slow to rise
in African P. falciparum populations because of genetic
background or other factors that are less supportive for
this haplotype than in South America. The impediment
posed by these factors remains open to question, however,
as laboratory experiments have shown that the N1042D
codon change can be crossed into the African background
(as demonstrated by results from the 7G8/Brazil × GB4/
Ghana cross [5]). High prevalence in this study of the
major pfmdr1-YYNY haplotype in pfcrt-CVIET-carrying
parasites is consistent with previous findings of linkage
disequilibrium between pfcrt-76T and pfmdr1-86Y poly-
morphisms [61-63].
Gadalla et al. Malaria Journal  (2015) 14:129 Page 8 of 10The diversity of the pfnhe1-ms-4760 repeat in Muheza
is similar to the diversity reported from other regions
where this repeat has been studied [41,45,46]. The ms-
4760-2 haplotype was not detected, consistent with the
absence of this haplotype from a previous report from
East Africa [46]. However, ms-4760-4 was observed in
ten samples, ms-4760-72 in two samples and ms-4760-79
in one sample; these forms of ms-4760 were not found in
previous work from East Africa [46] or in a recent study
from Mali [41]. In addition, two haplotypes (ms-4760-102
and ms-4760-103), which have not been previously re-
ported, were observed. A recent report found an associ-
ation of three DNNND repeats in ms-4760 and higher
IC50 for QN in Western Kenya [64]. The results of the
present study did not show this association of three
DNNND repeats in cases of returned parasitaemia after
QN treatment.
Several possible explanations may account for the fre-
quent recurrence of a parasitaemia within 28 days of
treatment and the lack of clear associations to known
pfcrt, pfmdr1 and pfnhe1 markers of AQ and QN resist-
ance. These include the high entomological inoculation
rates that may have contributed frequent reinfections
from emergent liver forms as drug levels wane after treat-
ment. The extent of clearance of moderately-resistant par-
asites carrying pfcrt-CVIET, pfmdr1-86Y, pfmdr1-1246Y
or pfnhe1 haplotypes of ≥ 2 DNNND repeats may have
been affected by the immune status of the children [65].
Finally, the authors note that anti-malarial treatments
were not fully supervised and plasma drug levels were not
followed as part of the parent study to this sub-study; un-
less disease severity warranted in-patient treatment, chil-
dren were released from the clinic with medicine and
instructions to the parents to complete the prescribed
treatment. Compliance and pharmacokinetics of the drugs
may have affected treatment efficacy, as has been reported
elsewhere [66-69].
Previous studies have documented the return of the
wild-type pfcrt-CVMNK haplotype of CQ-sensitivity in
parasite populations where alternative drugs including
ACT replaced CQ [7-18]. Tanzania changed its malaria
treatment policy from CQ to SP in 2001. Although a sta-
tistically significant increase of pfcrt-CVMNK in Muheza
over the period was not found in this study, the presence
of this wild-type form in the region may set the stage for
the return of increased prevalence of the pfcrt wild-type,
as CQ-sensitive parasites in the absence of selective pres-
sure have been observed elsewhere in Tanzania where CQ
therapy has also been removed [11]. Selection of opposite
alleles of pfmdr1 by ACT partner drugs, such as AQ and
lumefantrine [70], suggest that these drugs could be alter-
nated in order to prolong their efficacy.
Occurrence of the pfcrt-SagtVMNT haplotype in Africa
has been reported at low prevalence in countries otherthan Tanzania: examples include instances of this haplo-
type in Ghanaian samples collected in 1996-97 [60] and
recently from Cameroon [48]. Disparate findings can be
found in reports from Angola in 2007 and 2010, where
pfcrt-StctVMNT was detected in 58% of 102 samples
from Luanda [49], but there was a complete absence of
pfcrt-StctVMNT from 430 samples collected in Dande
[71]. Considering that Luanda and Dande are approxi-
mately 90 km apart, additional surveys will be needed to
establish the potential prevalence of pfcrt-StctVMNT in
this region.
Conclusions
Although the pfcrt-SVMNT haplotype associated with
amodiaquine resistance has been reported from Korogwe,
Tanzania, this study of 234 samples from Muheza, ap-
proximately 40 kilometers away and in the same time
period, did not detect this haplotype. The pfcrt-CVIET
haplotype widely responsible for chloroquine resistance
was most prevalent in this study and was significantly as-
sociated with the pfmdr1-YYNY haplotype. Low levels of
the wild-type pfcrt-CVMNK haplotype in Muheza may set
the stage for the return of chloroquine sensitive P. falcip-
arum populations, as has been reported in other regions
where chloroquine use was stopped. Relative absence of
pfcrt-SVMNT from Africa may reflect genetic or other
factors affecting P. falciparum that are less supportive for
this haplotype than in South America and other continen-
tal regions.
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